Is there a radiobiologic basis for improving the treatment of advanced stage cervical cancer?
The success of radiotherapy in eradicating the primary tumor in patients with locally advanced cervical cancer is limited by normal tissue tolerance. Systematic recording of morbidity and treatment parameters is therefore very important for radiobiologic treatment optimization and clinical decision making. There is substantial evidence that fractionation schedules employing large doses per fraction lead to a loss of therapeutic ratio. A similar argument could be used for high-dose-rate (HDR) brachytherapy that should also be administered in small dose fractions. However, HDR brachytherapy might convey some advantage to physical dose distribution that should be weighed against the radiobiologic advantages of low-dose-rate (LDR) continuous irradiation. Increasing overall treatment time reduces local control probability, whereas a shorter overall treatment time by accelerated fractionation may improve the therapeutic ratio, at least in fast-growing tumors. Hypoxia and reduced oxygen delivery are associated with poor radiation response. Anemia should be compensated, if necessary. The role of hypoxic modification needs to be further explored. In the future, the therapeutic ratio may also be improved by the use of chemical and biologic response modifiers. Tumors are heterogeneous with respect to intrinsic radiosensitivity, proliferation parameters, and extent of hypoxia. Until a detailed prognostic profile can be obtained for each patient, optimal curative radiotherapy must aim for a sufficient dose, short overall treatment time, hypoxic modification, and LDR or low dose per fraction.
Lindegaard
J C
JC
Danish Cancer Society, Department of Experimental Clinical Oncology, Aarhus University Hospital, Nørrebrogade, Denmark.
Overgaard
J
J
Bentzen
S M
SM
Pedersen
D
D
D001918:Brachytherapy / Q000379:methods; D002294:Carcinoma, Squamous Cell / Q000473:pathology* / Q000532:radiotherapy*; D004307:Dose-Response Relationship, Radiation; D005260:Female; D006801:Humans; D009367:Neoplasm Staging; D011836:Radiation Tolerance; D011879:Radiotherapy Dosage; D002583:Uterine Cervical Neoplasms / Q000473:pathology* / Q000532:radiotherapy*